Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Graffinity and Elan enter fragment-based discovery deal
February 2009
SHARING OPTIONS:

HEIDELBERG, GermanyŚGraffinity Pharmaceuticals GmbH announces that it has entered a research collaboration with Elan Pharmaceuticals Inc., a subsidiary of Dublin, Ireland-based Elan Corp. plc., under which Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a number of drug targets. In turn, Elan will gain access to Graffinity's proprietary fragment-based drug discovery technology, which uses chemical microarrays and surface plasmon resonance to screen for small molecule fragments that bind to a variety of drug targets. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed. DDN


Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.